The Human Medicines (Amendments relating to the Windsor Framework) Regulations 2024

Amendment to regulation C17

This section has no associated Explanatory Memorandum

9.  In regulation C17(1) (guidelines on good manufacturing practice and good distribution practice)(1), for “Great Britain” substitute “the United Kingdom”.

(1)

Regulation C17 was inserted by S.I. 2019/775 as amended by S.I. 2020/1488.